Clair Health Secures $11.6M for Noninvasive Wearable Hormone Monitor
Clair Health, founded by Stanford graduates, secured $11.6 million led by Khosla Ventures for a noninvasive wearable hormone monitor. The device tracks estrogen, progesterone, LH, and FSH using biosensors and AI. Shipping November 2024 as a wellness product, it requires future FDA clearance and currently lacks peer-reviewed results, aiming to provide continuous insights into women's hormonal health globally.
Key points
- Clair Health, a San Francisco startup co-founded by Stanford graduates Jenny Duan (21) and Abhinav Agarwal, has raised $11.6 million in seed funding.
- The funding round was spearheaded by Khosla Ventures, with contributions from investors including a16z speedrun and 23andMe co-founder Anne Wojcicki.
- The company is developing a continuous, noninvasive wristband that utilizes 10 biosensors and AI models to infer and track key hormones like estrogen, progesterone, LH, and FSH.
- Clair Health intends to ship the device in November 2024 as a wellness product, noting that FDA clearance is pending and peer-reviewed scientific results are not yet available for its technology.
- This innovation seeks to offer women detailed insights into their hormonal cycles, perimenopause, and health markers without requiring traditional blood-based measurements.
San Francisco-based startup Clair Health, co-founded by recent Stanford graduates Jenny Duan and Abhinav Agarwal, has successfully secured $11.6 million in seed funding. The substantial investment round was led by prominent venture capital firm Khosla Ventures, with additional participation from a16z speedrun, Brydge Club, and notable individual investors like 23andMe co-founder Anne Wojcicki.
The company is developing a groundbreaking noninvasive wearable device designed for continuous hormone monitoring. This wristband aims to track crucial hormones such as estrogen, progesterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) using a unique stack of 10 biosensors combined with proprietary AI algorithms. Unlike conventional methods, Clair Health’s technology interprets physiological signals like skin temperature and heart rate variability to identify over 130 biomarkers, providing a comprehensive view of a woman's hormonal cycle without the need for blood samples. The startup also incorporates voice-based onboarding to gather user-specific health data.
Clair Health plans to release its wearable product in November 2024. Initially, it will be marketed as a wellness product, as the company states that FDA clearance is slated to follow at a later stage. It is important to note that the technology has not yet undergone peer-reviewed scientific validation. This development represents a significant stride in personal health technology, particularly for women's health, offering a user-friendly way to understand cycle irregularities, perimenopause, and general hormonal fluctuations.
By offering continuous, accessible data on hormonal health, Clair Health aims to empower women with deeper insights into their bodies, potentially transforming how individuals track and manage their well-being on a global scale. The investment highlights a growing focus on innovative solutions for overlooked areas in healthcare, leveraging artificial intelligence and advanced sensor technology.
Sources
The WireByte editorial team synthesises technology news from multiple primary sources, verifies the facts, and links every source. Articles are produced with AI assistance and reviewed under our editorial policy.